Table 2. New dosage forms and indications approved by the FDA: April 19, 2015 through May 15, 2015.
| Generic name | Brand name (Company) | Indication and comments |
| New indications | ||
| Fluticasone furoate and vilanterol inhalation powder |
Breo Ellipta (GlaxoSmithKline) |
Treatment of asthma in patients 18 years and older |
| Moxifloxacin |
Avelox (Bayer Healthcare) |
Treatment of patients with plague |
| Ramucirumab |
Cyramza (Eli Lilly) |
Use in combination with FOLFIRI (leucovorin calcium, 5-fluorouracil, and irinotecan) for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab-, oxaliplatin-, and fluoropyrimidine-containing regimen. |